IBD: Reproductive health, pregnancy and lactation

Postgraduate Medical Journal

Volumn 91, Issue 1074, 2015, Pages 230-235

  Hendy, Philip ^a   Chadwick, Georgina ^a   Hart, Ailsa ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIBIOTIC AGENT; CORTICOSTEROID; CYCLOSPORIN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID; SALAZOSULFAPYRIDINE; THALIDOMIDE; TUMOR NECROSIS FACTOR INHIBITOR;

BREAST FEEDING; COLONOSCOPY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE CONTROL; DRUG SAFETY; FEMALE; FEMALE FERTILITY; HUMAN; INFLAMMATORY BOWEL DISEASE; LACTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PREGNANCY; PREGNANCY OUTCOME; PUERPERIUM; REPRODUCTIVE HEALTH; REVIEW; ULCERATIVE COLITIS;

EID: 84927752841     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2014-100430rep     Document Type: Review

References (45)

1. 1 Mañosa M, Navarro-Llavat M, Marín L, et al. Fecundity, pregnancy outcomes, and breastfeeding in patients with inflammatory bowel disease: a large cohort survey. Scand J Gastroenterol 2013;48:427–32.
2. 2 Hudson M, Flett G, Sinclair TS, et al. Fertility and pregnancy in inflammatory bowel disease. Int J Gynaecol Obstet 1997;58:229–37.
3. 3 Willoughby CP, Truelove SC. Ulcerative colitis and pregnancy. Gut 1980;21:469–74.
4. 4 Waljee A, Waljee J, Morris AM, et al. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 2006;55:1575–80.
5. 5 Beyer-Berjot L, Maggiori L, Birnbaum D, et al. A total laparoscopic approach reduces the infertility rate after ileal pouch-anal anastomosis: a 2-center study. Ann Surg 2013;258:275–82.
6. 6 Bartels SAL, D’Hoore A, CuestaMA, et al. Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy: a cross-sectional study. Ann Surg 2012;256:1045–8.
7. 7 Tavernier N, Fumery M, Peyrin-Biroulet L, et al. Systematic review: fertility in non-surgically treated inflammatory bowel disease. Aliment Pharmacol Ther 2013;38:847–53.
8. 8 Baird DD, Narendranathan M, Sandler RS. Increased risk of preterm birth for women with inflammatory bowel disease. J Gastroenterol 1990;99:987–94.
9. 9 Orholm M, Munkholm P, Langholz E, et al. Familial occurrence of inflammatory bowel disease. N Engl J Med 1991;324:84–8.
10. 10 Laharie D, Debeugny S, Peeters M, et al. Inflammatory bowel disease in spouses and their offspring. J Gastroenterol 2001;120:816–9.
11. 11 Beaulieu DB, Kane S. Inflammatory bowel disease in pregnancy. World J Gastroenterol 2011;17:2696–701.
12. 12 Miller JP. Inflammatory bowel disease in pregnancy: a review. J R Soc Med 1986;79:221–5.
13. 13 Alstead EM, Nelson-Piercy C. Inflammatory bowel disease in pregnancy. Gut 2003;52:159–61.
14. 14 Bush MC, Patel S, Lapinski RH, et al. Perinatal outcomes in inflammatory bowel disease. J Matern Fetal Neonatal Med 2004;15:237–41.
15. 15 Calderwood AH, Kane SV. IBD and Pregnancy. MedGenMed 2004;6:14.
16. 16 Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007;56:830–7.
17. 17 Van der Woude CJ, Kolacek S, Dotan I, et al. European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis 2010;4:493–510.
18. 18 Christensen LA, Rasmussen SN, Hansen SH. Disposition of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid in fetal and maternal body fluids during treatment with different 5-aminosalicylic acid preparations. Acta Obstet Gynecol Scand 1994;73:399–402.
19. 19 Rahimi R, Nikfar S, Rezaie A, et al. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol 2008;25:271–5.
20. 20 Colombel JF, Brabant G, Gubler MC, et al. Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? Lancet 1994;344:620–1.
21. 21 Mogadam M, Dobbins WO, Korelitz BI, et al. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 1981;80:72–6.
22. 22 Casanova MJ, Chaparro M, Domènech E, et al. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 2013;108:433–40.
23. 23 Akbari M, Shah S, Velayos FS, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:15–22.
24. 24 Coelho J, Beaugerie L, Colombel JF, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 2011;60:198–203.
25. 25 Jharap B, de Boer NKH, Stokkers P, et al. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut 2014;63:451–7.
26. 26 Teruel C, López-San Román A, Bermejo F, et al. Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines. Am J Gastroenterol 2010;105:2003–8.
27. 27 Feagins LA, Kane SV. Sexual and reproductive issues for men with inflammatory bowel disease. Am J Gastroenterol 2009;104:768–73.
28. 28 Francella A, Dyan A, Bodian C, et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: A retrospective cohort study. J Gastroenterol 2003;124:9–17.
29. 29 Perales-Puchalt A, Vila Vives JM, LópezMontes J, et al. Pregnancy outcomes after kidney transplantation-immunosuppressive therapy comparison. J Matern Fetal Neonatal Med 2012;25:1363–6.
30. 30 Bar Oz B, Hackman R, Einarson T, et al. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001;71:1051–5.
31. 31 Hoeltzenbein M, Stieler K, Panse M, et al. Allopurinol Use during Pregnancy—Outcome of 31 Prospectively Ascertained Cases and a Phenotype Possibly Indicative for Teratogenicity. PLoS One 2013;8:e66637.
32. 32 Miller SL, Wallace EM, Walker DW. Antioxidant therapies: a potential role in perinatal medicine. Neuroendocrinology 2012;96:13–23.
33. 33 Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011;17:1846–54.
34. 34 Bortlik M, Machkova N, Duricova D, et al. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study. Scand J Gastroenterol 2013;48:951–8.
35. 35 PIANO: A 1000 Patient Prospective Registry of Pregnancy Outcomes inWomenWith IBD Exposed to Immunomodulators and Biologic Therapy. http://download.journals.elsevierhealth.com/pdfs/journals/0016–5085/PIIS0016508512605617.pdf
36. 36 Heller MM, Wu JJ, Murase JE. Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab. J Am Acad Dermatol 2011;65:870.
37. 37 Bar-Oz B, Moretti ME, Boskovic R, et al. The safety of quinolones--a meta-analysis of pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol 2009;143:75–8.
38. 38 Cappell MS. Risks versus benefits of gastrointestinal endoscopy during pregnancy. Nat Rev Gastroenterol Hepatol 2011;8:610–34.
39. 39 Bulas D, Egloff A. Benefits and risks of MRI in pregnancy. Semin Perinatol 2013;37:301–4.
40. 40 Moffatt DC, Ilnyckyj A, Bernstein CN. A population-based study of breastfeeding in inflammatory bowel disease: initiation, duration, and effect on disease in the postpartum period. Am J Gastroenterol 2009;104:2517–23.
41. 41 Klement E, Cohen RV, Boxman J, et al. Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis. Am J Clin Nutr 2004;80:1342–52.
42. 42 Klotz U, Harings-Kaim A. Negligible excretion of 5-aminosalicylic acid in breast milk. Lancet 1993;342:618–19.
43. 43 Silverman DA, Ford J, Shaw I, et al. Is mesalazine really safe for use in breastfeeding mothers? Gut 2005;54:170–1.
44. 44 Nielsen OH, Maxwell C, Hendel J. IBD medications during pregnancy and lactation. Nat Rev Gastroenterol Hepatol 2014;11:116–27.
45. 45 Mahadevan U, Cucchiara S, Hyams JS, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol 2011;106:214–23.